CCM
GMAB icon

Camber Capital Management’s Genmab GMAB Stock Holding History

Camber Capital Management’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-50,000
Closed -$979K – 27
2025
Q1 		$979K Hold
50,000
– – 0.03% 32
2024
Q4 		$1.04M Hold
50,000
– – 0.02% 39
2024
Q3 		$1.22M Hold
50,000
– – 0.04% 33
2024
Q2 		$1.26M Hold
50,000
– – 0.03% 37
2024
Q1 		$1.5M Buy
+50,000
New +$1.47M 0.04% 36

Other funds holding GMAB

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Camber Capital Management's GMAB Position: Q2 2025 in Review

Camber Capital Management sold out of Genmab (GMAB) in Q2 2025, closing a stake of 50,000 shares — an estimated $979K sold.

Camber Capital Management first reported a position in GMAB in Q1 2024 and held it in 5 quarters. The position peaked at $1.5M in Q1 2024. 218 funds tracked by Wall St. Rank hold GMAB as of Q2 2025.

  • Camber Capital Management reported no remaining Genmab position as of Q2 2025 after selling out during the quarter.
  • Camber Capital Management sold 50,000 Genmab shares in Q2 2025, an estimated $979K.
  • Camber Capital Management first reported a position in Genmab in Q1 2024 and held it in 5 quarters.
  • Camber Capital Management's Genmab position peaked at $1.5M in Q1 2024.
  • 218 funds tracked by Wall St. Rank held Genmab as of Q2 2025.

Based on Camber Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.